Last reviewed · How we verify
Atropine 1%
Atropine blocks muscarinic acetylcholine receptors to inhibit parasympathetic activity, causing pupil dilation and cycloplegia when applied topically to the eye.
Atropine blocks muscarinic acetylcholine receptors to inhibit parasympathetic activity, causing pupil dilation and cycloplegia when applied topically to the eye. Used for Mydriasis and cycloplegia for diagnostic eye examinations, Accommodation disorders and strabismus management, Uveitis and anterior chamber inflammation.
At a glance
| Generic name | Atropine 1% |
|---|---|
| Also known as | Atropine sulfate, Atropine |
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Drug class | Anticholinergic agent / Muscarinic receptor antagonist |
| Target | Muscarinic acetylcholine receptors (M1-M5, primarily M3 in ocular tissue) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Atropine is an anticholinergic agent that competitively antagonizes muscarinic receptors in the iris sphincter muscle and ciliary muscle of the eye. This prevents acetylcholine-mediated contraction, resulting in mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). The 1% ophthalmic formulation is used diagnostically and therapeutically in ophthalmology.
Approved indications
- Mydriasis and cycloplegia for diagnostic eye examinations
- Accommodation disorders and strabismus management
- Uveitis and anterior chamber inflammation
Common side effects
- Blurred vision
- Photophobia
- Ocular irritation
- Systemic anticholinergic effects (if absorbed)
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Premedication for Less Invasive Surfactant Administration Study (PRELISA) (PHASE4)
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial (NA)
- Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PHASE4)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Changes of Ciprofol Dosage and Bispectral Index Required for Loss of Consciousness in Patients of Different Ages
- Combination Effect of Optical Defocus and Low Dose Atropine in Myopia Control (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atropine 1% CI brief — competitive landscape report
- Atropine 1% updates RSS · CI watch RSS
- Massachusetts Eye and Ear Infirmary portfolio CI